Prenetics Global Limited, a leader in the fields of genomic and diagnostic testing, is proud to announce the appointment of Dr. Bayju Thakar as CEO and member of the board of directors of its wholly owned subsidiary Prenetics EMEA Limited. This move is aimed at maximizing the potential of Prenetics’ genetic and digital testing platform, as well as a commitment to the EMEA market. The appointment will come into effect immediately.
We’re thrilled to announce the addition of Bayju Thakar as CEO of Prenetics EMEA! Bayju brings with him an impressive wealth of knowledge in digital health, medical and operating experience, having been the co-founder and ex-CEO of Doctor Care Anywhere, the UK’s largest telehealth primary care business with over 2 million lives. His expertise in the healthcare system dynamics, combined with Prenetics’ ambitions in the UK and EMEA markets, will undoubtedly be a great asset in helping Prenetics Global build a leading modern health ecosystem in EMEA and beyond. Danny Yeung, Chief Executive Officer of Prenetics Global Limited, is delighted to welcome Bayju Thakar and looks forward to the value his leadership will bring to all stakeholders.
I am excited to join Prenetics as the EMEA CEO and have the chance to work with Danny to build upon our strong foundation and further establish Prenetics as a leader in healthcare. Our team’s expertise, as well as our strong financial position, will enable us to grow organically and inorganically across a number of major healthcare opportunities, including primary and secondary care clinical services, IVF/fertility, and personalized cancer diagnostics.
Dr. Bayju Thakar Biography
Dr. Thakar brings over two decades of expertise in healthcare, digital health, M&A, strategic partnerships and board experience. Prior to co-founding Doctor Care Anywhere Group PLC – the UK’s largest telehealth primary care business with over two million lives under coverage – he was a practicing physician, both in General and Emergency medicine. Dr. Thakar holds a medical degree from King’s College, London, and is also a former McKinsey & Company consultant.
Prenetics was founded in 2014 with a mission to make health accessible to millions of people around the world. With operations across nine locations – the United Kingdom, Hong Kong, India, South Africa, and Southeast Asia – Prenetics offers comprehensive diagnostic and genetic testing services in the three main pillars of consumer health, clinical care, and medical & cancer genomics. As a leader in the field, Prenetics is proud to be listed on NASDAQ under the ticker PRE.